medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2013, Number 1

<< Back Next >>

Arch Neurocien 2013; 18 (1)

The use of magnesium sulfate in subarachnoid hemorrhage due to aneurysmal bleeding to prevent vasospasm

Ramírez-Barrios LR, Martínez-Ponce LÁ, Pérez-Cárdenas S, Guevara-Soria V

Language: Spanish
References: 10
Page: 39-41
PDF size: 96.74 Kb.


ABSTRACT

Objective: to determine the effectiveness of magnesium sulfate therapy for prevention of vasospasm in patients with subarachnoid hemorrhage from aneurismal rupture. Material and methods: twenty patients were included with subarachnoid hemorrhage from aneurismal rupture. The level of consciousness by the Glasgow Coma Scale, Fisher scale, Hunt & Hess scale were done and followed. The patients were split in two groups, one was given magnesium sulfated and triple H therapy and the second one only triple H therapy. The statistical analyze was done using Central tendency binary logistic regression and X2. Results: 15% of patients had neurological sequels at 21 days after the SAH, 10% died, of whom 50% had vasospasm. The presence of vasospasm differs in patients treated with magnesium sulfate, and was calculated by X2, but had no significant association (p = 0.383). Conclusions: treatment with magnesium sulfate in patients with SAH, does not help preventing neurological deterioration caused by vasospasm and had the same outcome as dose with no magnesium sulfate. This suggests that a study with more subjects is needed. Patients with lower fishers II or less had fewer complications.


REFERENCES

  1. Roda J, Conesa, G, Diez R, García A, Gómez, P González J, et al. Hemorragia subaracnoidea aneurismática. Introducción a algunos de los aspectos más importantes de esta enfermedad. Neurocirugía 2000; 3(2): 156-168.

  2. Lagares A, Gómez P, Alén J, Arikan F, Sarabia R, Horcajadas A, et al. Hemorragia subaracnoidea aneurismática: guía de tratamiento del Grupo de Patología Vascular de la Sociedad Española de Neurocirugía. Neurocirugía 2011; 22: 93-115.

  3. Sander E, Chair Jr, Rabintein A, Chair V, Carhuapoma J, Derdeyn C, et al. Guidelines for the Management of Aneurysmal. http:/ /stroke.ahajournals.org/content/early/2012/05/03/ STR.0b013e3182587839.full.pdf. Accessed: March 20, 2012.

  4. Prevedello D, Cordeiro J, de Moraias A, Saucedo N, Chen I, Araujo J. Magnesium sulfate: role as posible attenuating factor in vasoespasm morbidity. http://www.ncbi.nlm.nih. gov/pubmed/16427437. Accessed: July 20, 2012.

  5. Scherle-Matamoros C, Pérez-Nellar J, Fernández-Cue L. Vasoespasmo sintomático. Caracterización clínica. Neurocirugía 2011; 22: 116-22.

  6. Stippler M, Crago E, Levy E, Kerr M, Yonas H, Horowitz M, et al. Magnesium infusion for vasospasm prophylaxis after subarachnoid hemorrhage. J Neurosurg 2006;105(5):723-9.

  7. Veyna R, Seyfried D, Burke D, Zimmerman C, Mlynarek M, Nichols V, et al. Magnesium sulfate therapy after aneurismal subarachnoid hemorrhage. J Neurosurg 2002;96(3):510-4.

  8. Westermaier T, Stetter C, Vince G, Pham M, Tejon J, Eriskat J, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Critic Care Medic 2010; 38(5): 1284-90.

  9. Carrillo R, Leal P, Arellano R. Hemorragia subaracnoidea secundaria a ruptura de aneurisma. Medigraphic 2009: 16(1): 10-8.

  10. Rose J, Mayer S. Optimizing blood pressure in neurological emergencies. Neurocritic Care 2004;3:287-99.




2020     |     www.medigraphic.com